Systemic therapy represents the standard of care treatment for patients with advanced hepatocellular carcinoma (HCC). Given ...

The clinical trial will include nearly 150 patients with advanced hepatocellular carcinoma that expresses glypican-3.

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths worldwide, with over 70% of patients diagnosed at an advanced stage due to the absence of symptoms. A key characteristic ...

Bayer begins phase I study targeting GPC3 with actinium-225 radiopharmaceutical in patients with advanced hepatocellular carcinoma: Berlin Wednesday, April 30, 2025, 12:00 Hrs [IS ...

Here is a recap of every FDA approval announced by the regulatory agency in the month of April, spanning various cancer types ...

Bayer has launched a first-in-human clinical trial for 225Ac-GPC3 (BAY 3547926), a novel targeted alpha radiopharmaceutical ...

It had been recognised as a second-line treatment for advanced HCC patients treated ... "BMS’ Opdivo combo approved in US for hepatocellular carcinoma" was originally created and published ...

BAY 3547926 is an investigational targeted alpha radiopharmaceutical being developed to treat tumors expressing Glypican-3 (GPC3) in patients with advanced hepatocellular carcinoma (HCC).

in patients with advanced hepatocellular carcinoma (HCC). Oncofetal protein GPC3 is a membrane-associated proteoglycan which is overexpressed in 70-75% of HCC lesions making it an attractive ...

WHIPPANY, NJ, USA I April 29, 2025 I Bayer announced today initiation of a Phase I clinical trial with 225Ac-GPC3 (BAY 3547926), an investigational targeted ...